Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - cinacalcet hydrochloride, quantity: 99.18 mg (equivalent: cinacalcet, qty 90 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; pregelatinised maize starch; carnauba wax; crospovidone; povidone; colloidal anhydrous silica; hypromellose; macrogol 400; titanium dioxide; lactose monohydrate; indigo carmine; triacetin; iron oxide yellow - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). sensipar should be used as adjunctive therapy. sensipar is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma. sensipar may be used to treat the biochemical manifestations of primary hyperparathryoidism in patients for whom parathryoidectomy is not a treatment option.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - cinacalcet hydrochloride, quantity: 66.12 mg (equivalent: cinacalcet, qty 60 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; carnauba wax; magnesium stearate; microcrystalline cellulose; crospovidone; povidone; pregelatinised maize starch; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; triacetin; iron oxide yellow; macrogol 400 - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis (see clinical trials). sensipar should be used as adjunctive therapy. sensipar is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma. sensipar may be used to treat the biochemical manifestations of primary hyperparathryoidism in patients for whom parathryoidectomy is not a treatment option.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - cinacalcet hydrochloride, quantity: 33.06 mg (equivalent: cinacalcet, qty 30 mg) - tablet, film coated - excipient ingredients: carnauba wax; povidone; pregelatinised maize starch; magnesium stearate; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; triacetin; iron oxide yellow; macrogol 400 - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in patients with end stage renal disease, receiving dialysis. sensipar should be used as adjunctive therapy. sensipar is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma. sensipar may be used to treat the biochemical manifestations of primary hyperparathryoidism in patients for whom parathryoidectomy is not a treatment option.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - testosterone, quantity: 0.05 g - gel - excipient ingredients: purified water; sodium hydroxide; carbomer 980; ethanol; isopropyl myristate - indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - testosterone undecanoate, quantity: 40 mg - capsule, soft - excipient ingredients: propylene glycol monolaurate; hydrogenated castor oil; medium chain triglycerides; gelatin; sunset yellow fcf; lecithin; glycerol; titanium dioxide; propylene glycol; ethyl acetate; isopropyl alcohol; purified water; ethanol; strong ammonia solution; polyvinyl acetate phthalate; macrogol 400 - androgen replacement therapy for confirmed testosterone deficiency in males, when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Bandaríkin - enska - NLM (National Library of Medicine)

pure source, llc - benzyl alcohol 19% lidocaline hcl 4%, topical anesthetic - - for temporary relief of minor foot pain.

Ísrael - enska - Ministry of Health

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Ísrael - enska - Ministry of Health

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Ísrael - enska - Ministry of Health

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 45 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Ísrael - enska - Ministry of Health

incyte biosciences israel ltd, israel - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 45 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.